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Background.We aimed to study the prevalence of chronic comorbidities in asthmapatients and the costs of health care use associated
with asthma with comorbidities. Material and Methods. We analysed the prevalence of the four most common chronic diseases
in asthma patients in 2008–2014 in Finland. Prevalence of coronary artery disease, diabetes and dyslipidaemia, hypertension,
epilepsy, inflammatory bowel disease, rheumatic diseases, and severe psychiatric disease was studied by register of the Social
Insurance Institution of Finland. The costs of health care services were collected from the registries maintained by the National
Institute for Health and Welfare (THL). Results. Prevalence of asthma was 4.6% in 2014. Diabetes was among the four most
common comorbidities in all the age groups. The other common comorbidities were hypertension (≥46 years; 12.9–37.6%), severe
psychiatric disorders (age groups of 16–59 years; 1.4–3.5%), and ischaemic heart disease (≥60 years; 10–25%). In patients with both
asthma and diabetes, the costs of hospitalization were approximately 169% compared with patients with asthma alone. Conclusions.
Prevalence of asthma increases by tenfold when aging.The comorbidity diversity and rate are age-dependent. Prevalence of diabetes
as comorbidity in asthma has increased. Costs of hospitalizations in asthma approximately double with chronic comorbidities.
1. Introduction
Early diagnosis of asthma and effective asthma medica-
tion together with well-organized control options, patient
education, and self-management plans have led to major
decrease in asthma hospitalizations [1, 2]. Nonadherence to
antiasthmaticmedication, long-term smoking, and poor lung
function are risk factors for emergency department visits
[3, 4].Wehave earlier demonstrated that asthmahospital days
are highest in 0–5-year olds and in older than 75-year olds [5].
Usually comorbidity in asthma has been referred as
obesity, depression, or anxiety, reflux disease, or different
atopic disorders such as allergic rhinoconjunctivitis or atopic
eczema. Mostly asthma has been presented as a part of atopic
march or atopic constitution. Similarly, generalized systemic
inflammation has been represented as a cause for chronic
obstructive pulmonary disease and associated comorbidities
such as coronary artery disease and osteoporosis. If searching
for explanations for increased hospitalization rate in elderly
asthma patients, atopic disorders, obesity, or reflux disease
are unlikely to be causative factors and thus other systemic
diseases or associated comorbidities should be studied.
In here, we searched for explanations for marked increase
in asthma hospitalizations in the elderly by studying the
prevalence and variety of comorbidities of asthma patients
and health care costs associated with health care use. Comor-
bidities were assessed as chronic diseases entitling patients to
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higher than regular reimbursements for their drug costs by
the Finnish national health insurance.
2. Material and Methods
We explored what are the other chronic, comorbid diseases in
the Finnish asthma patients during a time period from 2008
to 2014. For that we used the nationwide Special Reimburse-
ment Register maintained by the Social Insurance Institution
(SII). In Finland, patients with defined chronic diseases
(e.g., asthma, diabetes, rheumatoid arthritis, coronary artery
disease, and hypertension) are entitled to higher than regular
reimbursement (special reimbursement) for their drug costs.
To be eligible for the higher reimbursement, the patient must
obtain a doctor’s certificate to confirm the diagnosis and
regular need for medication for persistent disease.
There are strict criteria for the special reimbursement of
asthma medication. The disease is required to be diagnosed
according to the international guidelines and variable airflow
limitation objectively shown according to the following
criteria: (1) forced expiratory volume in 1 second (FEV1)
improves at least 12% (200mL) after inhaling 𝛽2-agonist or
peak expiratory flow (PEF) improves at least 15% (60 L/min),
(2) PEF follow-up indicates diurnal variation of at least 20%
or at least 20% improvement in PEF level during asthma
treatment, or (3) bronchial responsiveness to histamine or
methacholine ismoderately or severely increased [3]. Asthma
patients were identified by the ICD10 classification codes for
J45 and J46.
Comorbidities to asthma were included by the Social
Insurance Institution special reimbursement for the accord-
ing comorbidity. The four most common comorbidities to
asthma were analysed. Comorbidity groups included diag-
noses for diabetes (E10–E14, E89.1), rheumatoid arthritis,
and other connective tissue diseases (A04.6, A39.8, A50.5,
D76.0, D76.3, H20.1, H30, I33.0, J84, K50.9, K51.9, K73.2,
K74.3, K83.0, L40.5,M02,M05,M06,M08,M13.9,M30–M35,
M45,M46.1, M46.9,M94.1, N03, andQ44.2), coronary artery
disease (I20–I22, I24.0, and I25), and hypertension (I10–I13,
I15, and I27.0) (Fimea). In addition, we searched for severe
psychiatric disorders (A52.1, A69.2, A81.0, B22.0, B56.9, B57.2,
E01.8, E03.9, E52, E53.8, E75.6, E83.0, E83.5, F01, F03, F20–
F25, F28, F29, F30.2, F31, F32.3, F33.3, F84, G10, G20, G30.0,
G30.1, G30.8, G30.9, G31.0, G35, G40.9, M30.0, and M32.8),
dyslipidemia associated with coronary artery disease (I20–
I22, I24.0, and I25), colitis ulcerosa and morbus Crohn (K50,
K51), and epilepsy (C71, G40, and G41).
Data for use of health care services were collected from
the National registries maintained by the National Institute
for Health and Welfare (THL). These registers included the
hospital benchmarking database [6] and the national dis-
charge registry (HILMO, [7]). Secondary care data included
the use of hospital outpatient care (all types of hospital visits)
and hospital inpatient admissions (DRGs).TheDRG costings
for hospitalizations and outpatient visits were based on
individual-level cost accounting data from several hospitals
and the same cost weights are used in the standard price list
reported by THL in the national level.
0.00 5.00 10.00 15.00 20.00 25.00
0–5-year olds
6–15-year olds
16–29-year olds
30–45-year olds
46–59-year olds
60–75-year olds
>76-year olds
Asthma patients in each age group (%) 
Proportion of age group
Proportion of asthmatics
Figure 1: Proportion of asthmatics in different age groups and
proportion of the age group of total population in 2014.
Standard population sizes in different age groups were
obtained from Statistics Finland [8].
Proportions (percentages) of asthma patients were cal-
culated from the total population and from the number of
people in the relevant age group. The number of asthma
patients with the comorbidity in question was adjusted for
the standard population size (100 000) according to the age
group.The four most common comorbidities to asthma were
analysed. The distribution of chronic diseases was calculated
by chi square test and using the Bonferroni correction for
multiple testing. Pearson correlation was used to analyse
correlation of asthma and diabetes. 𝑃 value < 0.05 was
considered statistically significant.
3. Results
In 2014 the number of asthmatics in the special reim-
bursement register was 251 540 (4.6% of the total Finnish
population). The absolute and relative number of asthmat-
ics increased with age as did the number of those with
various comorbidities (Figure 1, Table 1). In the oldest age
group approximately half of the asthma patients had another
chronic disease. Percentage of patients with persistent asthma
increased from 0–5-year olds (0.97%, 969 incident cases per
100 000 individuals of the whole population of the studied
age group) to 46–59-year olds (5.2%, 5236/100 000), to 60–75-
year olds (7.7%, 7705/100 000) and to over 75-year olds (9.9%,
9897/100 000).
The most common chronic comorbidity in the three
oldest age groups was (46 years or older) hypertension
with prevalence increasing from 12.9 to 37.6% (676/100 000;
2228/100 000 and 3723/100 000 individuals) according to
group (Table 1, Figure 2). Diabetes was among the four
most common comorbidities in all the age groups and its
prevalence was 17.5–18.8% in the two oldest age groups of
asthma patients (≥60 years) (1353/100 000 and 1856/100 000
individuals). The other common comorbidities were severe
psychiatric disorders with the prevalence varying from 1.4
to 3.5% (29/100 000 individuals, 91/100 000 and 183/100 000)
(three age groups of asthma patients 16–59 years) and
ischemic heart disease with the prevalence varying from 10.0
to 25.0% (774/100 000 and 2474/100 000) (two age groups of
asthma patients of ≥60 years (Table 1, Figure 2)).
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Table 1:The four most common comorbidities in asthma patients in different age groups according to Special Reimbursement Register. Total
numbers of asthmatic patients, asthmatic patients with the disease, and all the patients with the diseases in year 2014.
Age group Disease
Number of patients
with chronic disease
and asthma
Number of patients
with chronic disease
Number of patients with
asthma and special
reimbursement for
medication
Total population
0–5-year
olds
Epilepsy and comparable
convulsive disorders 28 713
3 508 362 128
Chronic cardiac
insufficiency 11 158
Diabetes mellitus 10 450
Treatment-resistant
epilepsy 9 245
6–15-year
olds
Epilepsy 135 2 307
14 746 594 087
Diabetes mellitus 101 3 923
Rheumatoid arthritis and
comparable conditions 76 1 714
Treatment-resistant
epilepsy 43 794
16–29-year
olds
Epilepsy 285 8 769
19 099 929 208
Psychosis and other severe
psychiatric diseases 268 8 819
Ulcerative colitis and
Crohn’s disease 176 5 183
Diabetes mellitus 161 9 132
30–45-year
olds
Psychosis and other severe
psychiatric diseases 982 20 723
37 292 1 082 178
Diabetes mellitus 976 19 326
Chronic hypertension 919 12 905
Rheumatoid arthritis and
comparable conditions 771 14 483
46–59-year
olds
Chronic hypertension 7 031 83 251
54 439 1 039 779
Diabetes mellitus 4 905 60 454
Rheumatoid arthritis and
comparable conditions 2 046 24 895
Psychosis and other severe
psychiatric diseases 1 901 26 901
60–75-year
olds
Chronic hypertension 23 081 224 435
79 825 1 036 018
Diabetes mellitus 14 013 137 319
Chronic coronary artery
disease and associated
dyslipidemia
8 016 76 456
Rheumatoid arthritis and
comparable conditions 4 146 38 588
76-year
olds
Chronic hypertension 16 037 145 447
42 634 430 757
Chronic coronary artery
disease and associated
dyslipidemia
10 657 84 940
Diabetes mellitus 7 995 70 104
Dyslipidaemia associated
with chronic coronary
heart disease
5 282 42 642
Proportion of asthma patients with at least one comor-
bidity increased considerably with age. In the oldest age
group (75 years or older), 37.6% had hypertension (3223/
100 000), 25.0% ischemic heart disease (2474/100 000), 18.8%
diabetes (1856/100 000), and 12.4% dyslipidaemia (1226/
100 000) (Table 1, Figure 2). In asthmatics, the distribution of
the four most common other reimbursed chronic diseases
was significantly different in all age groups (𝑃 < 0.00001)
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Figure 2: Four most common comorbidities among patients with persistent asthma in different age groups according to Social Insurance
Institution register data from 2008 to 2014 (from top and light grey to bottom and dark green of a bar).
compared with the total population, also after Bonferroni
correction for multiple testing.
Asthma patients with diabetes had increased from 2008
to 2014 which is a trend found also in general population.
Diabetes increased from 12.3% to 17.6% (𝑃 < 0.001) in the
60–75-year-old asthmatics and from 13.3% to 18.8% in those
over 75 years (𝑃 < 0.001) (Figure 2). Prevalence of diabetes
(both type I and type II) was 5.5% in the total population and
11.2% among all the asthma patients, thus showing a twofold
prevalence among asthmatics (Figure 3, Table 2). Prevalence
of asthma correlated with diabetes (𝑟 = 0.936, 𝑃 = 0.002).
In contrast, hypertension decreased in the 46–59-year-
old asthmatics from 17.3% to 12.9% during the same time
period (𝑃 < 0.001). In spite of the increased prevalence of
ischemic heart disease in older age groups the prevalence
of reimbursed chronic coronary artery disease decreased in
the age group of 60–75-year-old asthmatics from 14.5% to
10.0% (𝑃 < 0.001).
During the observed period, the costs of hospitalizations
caused by asthma were approximately 1217 C/year/patient. In
patients with both asthma and diabetes together, the costs
were approximately 69% higher compared to those with
asthma only. In patients with asthma and ischaemic heart dis-
ease the costs of hospitalizations were 191% higher compared
to asthma alone and in asthma and heart insufficiency the
costs were 259% higher than in those with asthma alone.
4. Discussion
Prevalence of asthma increases from 0.97% to 9.9% when
aging. Comorbidities to asthmawere different in the youngest
and the oldest age groups except for diabetes. In addition, the
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Table 2: Distribution of asthma and diabetes patients in the total population in 2014.
Age Diabetes (all) % (of the totalpopulation) Asthma (all)
% (of the total
population)
Asthma and
diabetes
% (of total
population)
Total
population
0–5 years 450 0.12 358 0.098 10 0.0028 362128
6–15 years 3923 0.66 14746 2.5 101 0.017 594087
16–29 years 9132 0.98 19099 2.1 161 0.017 929208
30–45 years 19326 1.8 37292 3.4 976 0.09 1082178
46–59 years 60454 5.8 54439 5.2 4905 0.47 1039779
60–75 years 137319 13.3 79825 7.7 14013 1.4 1036018
76 years and older 70104 16.3 42634 9.9 7995 1.9 430757
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Figure 3: Number and distribution of asthma and diabetes patients
according to age.
prevalence of comorbidities increases in older populations
accordingly. In the 0–5-year-old asthma patients, 0.20% had
epilepsy or other comparable convulsive disorders. In our
study, 28.9% of the 60–75-year-old asthma patients and
37.6% of at least 75-year-old asthma patients had chronic
hypertension. The most often found comorbidities differed
according to the age groups, but hypertension, chronic coro-
nary heart disease, diabetes, and severe psychiatric disorders
were the most often associated chronic diseases in patients
with asthma. Percentage of asthmatics with diabetes had
increased and was 11.2% in the total asthma population
whereas prevalence of diabetes was 5.5% in the total popu-
lation.
These nationwide statistics on medication compensation
are in accordance with the information obtained from ques-
tionnaire studies showing that asthma is the one of the most
prevalent chronic diseases of all ages and that chronic comor-
bidities of asthma patients follow the distribution of chronic
diseases in overall population. Epilepsy or other comparable
convulsive disorders were found in the youngest age groups
of asthma patients; severe psychiatric disorders, diabetes, and
rheumatoid arthritis were in the middle age groups whereas
chronic hypertension, chronic coronary heart disease, and
diabetes were among the most common chronic diseases in
the oldest age groups of asthma patients. Having diabetes as
comorbidity to asthma increased the hospitalization costs by
69%.
In France, 40.2% of the patients with severe asthma had
at least one chronic comorbidity [9]. Every other US adult
asthma patients have been reported to have at least one other
chronic condition [10]. In our study, 37.6% of 75-year-old or
older asthma patients had chronic hypertension which was
the most common single chronic disease in asthma patients.
In a Norwegian study, 8–19-year-old male asthmatics had
4.6 times increased odds ratio for gastrooesophageal reflux
disease (GERD), 4.2 for allergy, and 1.8 for epilepsy. In female
asthmatics of the same age, odds ratio was increased by 4.8
for having allergy, by 4.0 for having GERD, and by 2.0 for
having epilepsy [11]. Epilepsy was the most common chronic
disease in our study in age groups from 0 to 29 years. In a
US child study population aged 0–17 years odds for having
epilepsy were 2.3 in those with lifetime prevalence of asthma
and 2.0 in those with one-year prevalence of asthma [12].
However, the possible mechanisms for this association are
unknown. In older age groups other diseases than epilepsy
were more prominent. Further, the prevalence of allergy and
gastrooesophageal disease could not be estimated in our
study since neither entitles patients to special reimburse-
ments for drugs costs. However, both allergy and GERD are
widely accepted and known disorders in asthmatics and lately
GERD has been associated with neutrophilic asthma [9, 13–
15]. In the sameNorwegian study it was shown that odds were
increased by 1.6–2.1 for purchasing antibacterial and antiviral
drugs in asthma patients. Our study was limited only to data
on chronic diseases which do not include short courses of
antibacterial and antiviral drugs.
Further, in aCanadian population-based study on asthma
and health care service use, comorbidities were associated
with 5.5–7.6% of ambulatory claims, emergency department
visits, and hospitalizations [16]. In a later paper of Gershon
et al., comorbidity to asthmawas studied by physician claims.
Also in their study spectrum of other diseases to asthma
varied in different age groups. Other respiratory disorders
than asthma (acute bronchitis, pneumonia) were common in
all ages [17]. Psychiatric disorders and metabolic and immu-
nity disorders were often found causes for physician claims
in the youngest age group. Our results are in accordance
since epilepsy, diabetes, and rheumatic diseases were the
most common found disorders in our study in 0–15-year-old
asthmatics. Psychiatric disorder and infectious diseases were
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the most common disorders in the age groups of 18–44-
and 45–64-year-old asthmatics for physician claims in the
Canadian study [18]. In our study, psychiatric disorders were
among the four most common chronic comorbidities in 16–
59-year-old asthmatics.
If focusing on older age groups, we found that chronic
hypertension, diabetes, coronary disease, and hyperlipi-
daemia are the most common comorbidities. In a study of
severe asthma patients of mean age of 56 years 11.9% of
the asthmatic had diabetes, 16.5% osteoporosis, and 21.1%
hypertension [9]. This is also in accordance with our results
with diabetes being the second or third most common
comorbidity in those of 60 years or older (17.6–18.8%) and
hypertension being the most common chronic comorbidity,
accordingly (prevalence 28.9–37.6%).
Obesity is associated with asthma both as a risk factor
for severe asthma and as a risk factor for development
of asthma [19, 20]. Further, whether asthma could lead to
morbid obesity has also been suggested, for example, by
decreasing physical activity. Lately, a common pathogenetic
cause for both asthma and obesity has been introduced
[21, 22]. Chitinase 3-like 1 (CHI3L1) deficient mice have
been reported to develop less visceral obesity. Likewise,
overexpression of CHI3L1 induced obesity and increased
allergic airway inflammation in association with high-fat
diet. Increasing obesity at the population level is also the
main cause for increasing prevalence of type II diabetes.
In this study, we could not distinguish between type I and
type II diabetes or characterize severity of asthma. A link
between asthma and diabetes has been introduced not only
in predisposition but also in treatment of these diseases. In
a recent study, insulin was shown to suppress inflammatory
pathway in obese individuals with type II diabetes [23].
Insulin decreased mRNA expression of IL-4, ADAM-33, and
LTBR (lymphotoxin beta receptor), which are all potentially
involved in pathogenesis of asthma.
Although both asthma and rheumatoid arthritis are
inflammatory diseases they are seldom described to be
associated probably because asthma is usually associated
with Th2-type inflammation and rheumatoid arthritis is
considered to be originated of Th1-type inflammation. In
a Taiwanese study with 27 602 patients with rheumatoid
arthritis, asthma incidence was reported to be twice (4.56 per
1000 person-years) compared to the general population (2.22
per 1000 person-years) [24]. We studied prevalence and not
incidence, but rheumatoid arthritis was among the four most
common chronic comorbidities in asthma patients in 6–15-
year olds and 30–75-year olds. In 16–29-year old asthmatics,
other inflammatory diseases such as ulcerative colitis and
Crohn’s disease were the third most common comorbidities.
Asthma has been associated with anxiety and depression
in many studies [25, 26]. In a recent meta-analysis of
allergy related cytokines in depression, IL1, IL4, IL6, and
TNF-𝛼, were found increased in depression compared to
nondepressive study subjects and were considered to be a
possible inflammatory link between the two disorders [27].
A possible common susceptibility to both asthma and anxiety
or depression either in the formof inflammatorymechanisms
or genetic factors is supported by an epidemiologic study by
Goodwin et al. [25]. They found increased odds for preva-
lence of concurrent or persistent anxiety and depression in
patients with respiratory disease. In our study, 3.5% of the 46–
59-year-old asthma patients suffered from psychosis or other
severe psychiatric diseases and had received reimbursement
for both disorders.
Morbidity increases together with age and, accordingly,
the rate of comorbidities in asthma patients is age-dependent.
The World Health Organization (WHO) has estimated that
noncommunicable diseases account for 63% of all deaths
[28]. In our study, chronic hypertension, diabetes, coro-
nary disease, and hyperlipidaemia were the most common
comorbidities to asthma following age-dependent disease
distribution of a normal population. Both asthma and dia-
betes affect individuals of all age groups, with asthma being
more common in children and adolescents and diabetes in
the elderly (Figure 3). Although asthma is among the four
most common noncommunicable diseases (cardiovascular
diseases, chronic respiratory diseases, cancers, and diabetes)
it is noteworthy that malignancies were not found in our
study for comorbidities in asthma not even in the oldest age
groups.
Medication costs of asthma have increased while hos-
pitalizations and physician visits have decreased [1, 18].
However, it is known that hospitalizations accumulate in the
youngest and in the oldest age groups of asthma patients.
Further, less is known of the costs’ increase associated with
comorbidity. Here, we found an increase from 169% to
359% in asthma hospitalizations associated with chronic
comorbidity.
5. Conclusions
Prevalence of asthma increases by tenfold when aging.
The most common other reimbursed chronic conditions in
addition to asthma in the youngest age groups were epilepsy
or other comparable convulsive disorders. In the middle
aged asthmatics, severe psychiatric disorders, diabetes, and
rheumatoid arthritis predominated. Hypertension, coronary
heart disease, and diabetes were among the most common
chronic diseases in the oldest age groups of asthma patients.
Hospitalizations in persistent asthma increase considerably
in the age group over 75 years compared to other age groups
and it is possible that chronic cardiovascular comorbidity has
a major role in the hospitalizations associated with asthma
in the oldest age group. Chronic diseases as comorbidity
increase significantly the costs of hospitalizations in asthma
patients.
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